title: Amoxicillin for postexposure inhalational anthrax in pediatrics: rationale for dosing recommendations.
abstract: We reviewed information about the safety and plasma pharmacokinetic data for amoxicillin, specifically related to its potential use for postexposure inhalational anthrax. Amoxicillin (45 mg/kg/d) given orally in 3 divided doses to pediatric patients <40 kg should yield an adequate time above the MIC for susceptible Bacillus anthracis (< or =0.5 microg/mL) over most of the dosing interval (75-100%). Doses <45 mg/kg/d and dosing intervals longer than 8 hours should not be used for postexposure inhalational anthrax.
authors.affiliation: Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
authors.forename: John J
authors.initials: JJ
authors.lastname: Alexander
authors.forename: Philip M
authors.initials: PM
authors.lastname: Colangelo
authors.forename: Charles K
authors.initials: CK
authors.lastname: Cooper
authors.forename: Rosemary
authors.initials: R
authors.lastname: Roberts
authors.forename: William J
authors.initials: WJ
authors.lastname: Rodriguez
authors.forename: Mary D
authors.initials: MD
authors.lastname: Murphy
mesh_terms: D000658:Amoxicillin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000881:Anthrax / Q000188:drug therapy / Q000517:prevention & control*; D001408:Bacillus anthracis / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D019570:Inhalation Exposure; D008826:Microbial Sensitivity Tests
chemical_list: D000658:Amoxicillin